Entrada Therapeutics TRDA
NASDAQ TRDA
$4.57 -0.08 (-1.61%)
As of: Oct 22, 2026 · 9:50 AM EDT

Entrada Therapeutics (TRDA) Short-term Investments (2022)

Updated

Entrada Therapeutics' Short-term Investments came in at $162.26 million for Q3 2022, up 5.8% from the prior quarter.

Analysis

Entrada Therapeutics (TRDA) Short-term Investments (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,157.52 Bn 1,126.11 Bn 19.71 Bn
2 Johnson & Johnson 631.39 Bn 549.92 Bn 17.26 Bn
3 AbbVie 498.93 Bn 472.04 Bn 12.70 Bn
4 Merck 376.05 Bn 330.42 Bn 12.21 Bn
5 Novartis Ag 301.98 Bn 265.97 Bn 11.24 Bn
6 Astrazeneca 265.05 Bn 238.74 Bn 12.86 Bn
7 Amgen 240.27 Bn 195.67 Bn 7.24 Bn
8 Gilead Sciences 193.08 Bn 167.27 Bn 6.22 Bn
9 Pfizer 171.85 Bn 118.50 Bn 10.94 Bn
10 Entrada Therapeutics 193.16 Mn -166.24 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 162.26 Mn
Jun 30, 2022 153.39 Mn
Mar 31, 2022 179.26 Mn
API Access

Entrada Therapeutics Short-term Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-investments&ticker=TRDA&period=max&api_key=YOUR_API_KEY